As
filed with the Securities and Exchange Commission on June 15,
2009
|
Registration
No. 333-
|
Ireland
|
Not
Applicable
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification Number)
|
ICON
plc
South
County Business Park
Leopardstown,
Dublin 18
Ireland
(353)
1-291-2000
(Address
and telephone number of Registrant’s
principal
executive offices)
|
CT
Corporation System
111
Eighth Avenue
New
York, New York 10011
(212)
590-9332
(Name,
address and telephone number of
agent
for service)
|
Ciaran
Murray
Chief
Financial Officer ICON plc
South
County Business Park
Leopardstown,
Dublin 18, Ireland
(353)
1-291-2000
|
William
M. Hartnett, Esq.
Cahill
Gordon & Reindel LLP
80
Pine Street
New
York, New York 10005
(212)
701-3000
|
Title
of each class of
securities
to be registered
|
Amount
to be registered
|
Proposed
maximum
aggregate
price per
unit
|
Proposed
maximum
aggregate
offering price
|
Amount
of registration fee
|
||||||
Debt
Securities (1)
|
||||||||||
Convertible
Debt Securities (1)
|
||||||||||
Ordinary
Shares (represented by American Depositary Shares) (1)
|
||||||||||
Total
|
(1)
|
(1)
|
(1)
|
$11,160(2)
|
●
|
we
may offer and sell ordinary shares, par value €0.06 per share, in the form
of American Depositary Shares, or ADSs, covered by this prospectus from
time to time in one or more offerings, which may be through one or more
underwriters, dealers and agents, or directly to the purchasers. The names
of any underwriters, dealers or agents, if any, will be included in a
supplement to this prospectus;
|
|
●
|
we
may also issue debt securities covered by this prospectus from time to
time in one or more offerings, which may be through one or more
underwriters, dealers and agents, or directly to the purchasers. The names
of any underwriters, dealers or agents, if any, will be included in a
supplement to this prospectus;
|
|
●
|
we
may also issue convertible debt securities, which under certain
conditions, may be converted into our ordinary shares, in the form of
ADSs, covered by this prospectus from time to time in one or more
offerings, which may be through one or more underwriters, dealers and
agents, or directly to the purchasers. The names of any underwriters,
dealers or agents, if any, will be included in a supplement to this
prospectus; and
|
|
●
|
the
prospectus supplement will provide specific information about the terms of
that offering and the terms of the securities and also may add, update or
change information contained in this
prospectus.
|
Page
|
|||
About
this Prospectus
|
4
|
||
Disclosure
Regarding Forward-Looking Statements
|
5
|
||
About
the Registrant
|
6
|
||
Risk
Factors
|
7
|
||
Ratio
of Earnings to Fixed Charges
|
8
|
||
Use
of Proceeds
|
9
|
||
Capitalization
|
10
|
||
Price
Range of ADSs and Dividend Policy
|
11
|
||
Description
of Ordinary Shares and American Depositary Shares
|
13
|
||
Description
of Debt Securities
|
19
|
||
Description
of Convertible Debt Securities
|
29
|
||
Irish
Taxation Considerations
|
38
|
||
Plan
of Distribution
|
42
|
||
Exchange
Controls and Other Limitations Affecting Security Holders
|
45
|
||
Validity
of the Securities
|
45
|
||
Experts
|
45
|
||
Enforceability
of Civil Liabilities Provisions of Federal Securities Laws Against Foreign
Persons; Shareholder Rights Under Irish Law
|
46
|
||
Additional
Information
|
47
|
||
Incorporation
of Documents by Reference
|
47
|
||
Part
II - Information Not Required in Prospectus
|
|||
Indemnification
of Directors and Officers
|
II-1
|
||
Exhibits
|
II-2
|
||
Undertakings
|
II-3
|
ABOUT
THE REGISTRANT
|
||
ICON
|
||
We
are a contract research organization (“CRO”), providing outsourced
development services on a global basis to the pharmaceutical,
biotechnology and medical device industries. We specialize in the
strategic development, management and analysis of programs that support
Clinical Development - from compound selection to Phase I-IV clinical
studies. We have the operational flexibility to provide development
services on a stand-alone basis or as part of an integrated “full service”
solution. Our preferred approach is to use dedicated teams to achieve
optimum results, but we can implement a range of resourcing models to suit
client requirements, and increasingly our teams are flexibly applied to
minimize costs for our clients.
|
||
In
a highly fragmented industry, we are one of a small number of companies
with the capability and expertise to conduct clinical trials in all major
therapeutic areas on a global basis. We have the operational flexibility
to provide development services on a stand-alone basis or as part of an
integrated “full service” solution.
|
||
Headquartered
in Dublin, Ireland, we began operations in 1990 and have expanded our
business through internal growth and strategic
acquisitions.
|
||
Our
ADSs are listed and traded on The Nasdaq National Market under the symbol
“ICLR.”
|
||
Risks
Related to Our Business and Our Securities
|
||
Before
making an investment decision, you should carefully consider the risks
described under “Risk Factors” in the applicable prospectus supplement and
in our most recent Annual Report on Form 20-F, and in our updates, if any,
to those Risk Factors in our periodic reports on Form 6-K, together with
all of the other information appearing in this prospectus or incorporated
by reference into this prospectus and any applicable prospectus
supplement, in light of your particular investment objectives and
financial circumstances. In addition to those Risk Factors, there may be
additional risks and uncertainties of which management is not aware or
focused on or that management deems immaterial. Our business, financial
condition or results of operations could be materially adversely affected
by any of these risks. The trading price of our securities could decline
due to any of these risks, and you may lose all or part of your
investment.
|
||
Our
principal executive offices are located in South County Business Park,
Leopardstown, Dublin 18, Ireland and our telephone number is (353)
1-291-2000.
|
||
Year
Ending
Dec.
31, 2008
|
Year
Ending
Dec.
31, 2007
|
Year
Ending
Dec.
31, 2006
|
Period
Ending
Dec.
31, 2005(1)
|
Year
Ending
May
31, 2005 (3)
|
Year
Ending
May
31, 2004
|
|||||||
Ratio
of earnings to fixed charges (2)
|
19.29x
|
36.16x
|
382.53x
|
525.09x
|
130.49x
|
170.21x
|
As
of
December
31, 2008
|
||||
(in
thousands)
|
||||
Cash
and cash equivalents
|
$
|
58,378
|
||
Short-term
investments (available for sale)
|
$
|
42,726
|
||
Bank
credit lines and loan facilities (1)
|
$
|
105,379
|
||
Shareholders’
equity:
|
||||
Ordinary
Shares, par value €0.06 per share: 100,000,000 shares authorized;
58,518,195 shares issued and outstanding
|
4,921
|
|||
Additional
paid-in capital
|
162,057
|
|||
Accumulated
other comprehensive income
|
3,178
|
|||
Retained
earnings
|
286,210
|
|||
Total
shareholders’ equity
|
456,366
|
|||
Total
capitalization
|
$
|
456,366
|
(1)
|
For
a discussion of our indebtedness, see “Item 5. Operating and Financial
Review and Prospects—Liquidity and Capital Resources” in our
Form 20-F for the period ended December 31, 2008, which is
incorporated by reference
herein.
|
Year
Ending*
|
High
Sales Price
During
Period
|
Low
Sales Price
During
Period
|
|||
May
31, 2004
|
$11.52
|
$ 6.47
|
|||
May
31, 2005
|
$11.23
|
$ 7.57
|
|||
Dec.
31, 2005 (7 month transition period)
|
$12.63
|
$ 7.53
|
|||
Dec.
31, 2006
|
$20.18
|
$10.25
|
|||
Dec.
31, 2007
|
$32.40
|
$18.34
|
|||
Dec.
31, 2008
|
$44.78
|
$15.64
|
|||
Quarter
Ending*
|
|||||
Mar.
31, 2007
|
$22.30
|
$18.34
|
|||
June
30, 2007
|
$24.83
|
$20.83
|
|||
Sept.
30, 2007
|
$26.63
|
$21.26
|
|||
Dec.
31, 2007
|
$32.40
|
$25.36
|
|||
Mar.
31, 2008
|
$35.56
|
$28.63
|
|||
June
30, 2008
|
$39.12
|
$29.52
|
|||
Sept.
30, 2008
|
$44.78
|
$35.00
|
|||
Dec.
31, 2008
|
$39.66
|
$15.64
|
|||
Mar.
31, 2009
|
$24.77
|
$15.07
|
|||
Month
Ending*
|
|||||
Oct.
31, 2008
|
$39.66
|
$18.67
|
|||
Nov.
30, 2008
|
$27.90
|
$15.64
|
|||
Dec.
31, 2008
|
$24.37
|
$17.27
|
|||
Jan.
31, 2009
|
$22.99
|
$18.25
|
|||
Feb.
28, 2009
|
$24.77
|
$19.50
|
|||
Mar.
31, 2009
|
$21.41
|
$15.07
|
|||
April
30, 2009
|
$18.59
|
$12.17
|
|||
May
31, 2009
|
$17.94
|
$14.45
|
●
|
the
title of the debt securities;
|
●
|
the
price or prices (expressed as a percentage of the aggregate principal
amount) at which we will sell the debt securities;
|
●
|
any
limit on the aggregate principal amount of the debt
securities;
|
●
|
the
date or dates on which we will pay the principal on the debt
securities;
|
●
|
the
rate or rates (which may be fixed or variable) per annum or the method
used to determine the rate or rates (including any commodity, commodity
index, stock exchange index or financial index) at which the debt
securities will bear interest, the date or dates from which interest will
accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest
payment date;
|
●
|
the
place or places where principal of, premium, and interest on the debt
securities will be payable;
|
●
|
the
terms and conditions upon which we may redeem the debt
securities;
|
●
|
any
obligation we have to redeem or purchase the debt securities pursuant to
any sinking fund or analogous provisions or at the option of a holder of
debt securities;
|
●
|
the
dates on which and the price or prices at which we will repurchase the
debt securities at the option of the holders of debt securities and other
detailed terms and provisions of these repurchase
obligations;
|
●
|
the
denominations in which the debt securities will be issued, if other than
denominations of $1,000 and any integral multiple
thereof;
|
●
|
whether
the debt securities will be issued in the form of certificated debt
securities or global debt securities;
|
●
|
the
portion of principal amount of the debt securities payable upon
declaration of acceleration of the maturity date, if other than the
principal amount;
|
●
|
the
manner in which the amounts of payment of principal of, premium or
interest on the debt securities will be determined, if these amounts may
be determined by reference to an index based on a currency or currencies
other than that in which the debt securities are denominated or designated
to be payable or by reference to a commodity, commodity index, stock
exchange index or financial index;
|
●
|
any
provisions relating to any security provided for the debt
securities;
|
●
|
any
addition to or change in the Events of Default described in this
prospectus or in the indenture with respect to the debt securities and any
change in the acceleration provisions described in this prospectus or in
the indenture with respect to the debt securities;
|
●
|
any
addition to or change in the covenants described in this prospectus or in
the indenture with respect to the debt securities;
|
●
|
any
other terms of the debt securities, which may modify or delete any
provision of the indenture as it applies to that series;
and
|
●
|
any
depositaries, interest rate calculation agents, exchange rate calculation
agents or other agents with respect to the debt
securities.
|
●
|
the
principal of, premium, if any, and accrued and unpaid interest on, whether
outstanding on the date of execution of the indenture or thereafter
created, incurred or assumed;
|
●
|
our
indebtedness for money borrowed, other than the subordinated debt
securities;
|
●
|
guarantees
by us of indebtedness for money borrowed of any other
person;
|
●
|
indebtedness
evidenced by notes, debentures, bonds or other instruments of indebtedness
for the payment of which we are responsible or liable, by guarantees or
otherwise;
|
●
|
our
obligations under any agreement relating to any interest rate or currency
swap, interest rate cap, interest rate collar, interest rate future,
currency exchange or forward currency transaction or any similar interest
rate or currency hedging transaction, whether outstanding on the date of
the indenture or thereafter created, incurred or
assumed;
|
●
|
our
obligations under any agreement to lease, or any lease of, any real or
personal property which, in accordance with generally accepted accounting
principles, is classified on our balance sheet as a liability;
and
|
●
|
modifications,
renewals, extensions and refundings of any such indebtedness, liability,
obligation or guarantee;
|
●
|
such
default is cured or waived; or
|
●
|
unless
such default is a failure by us to pay principal or interest on any senior
indebtedness, 120 days pass after the notice is given if such default is
not the subject of judicial
proceedings.
|
●
|
the
successor person is a corporation, limited liability company, partnership,
trust or other entity organized and validly existing under the laws of the
Republic of Ireland or any U.S. domestic jurisdiction and expressly
assumes our obligations on the debt securities and under the
indenture;
|
●
|
immediately
after giving effect to the transaction, no Event of Default, and no event
which, after notice or lapse of time, or both, would become an Event of
Default, shall have occurred and be continuing under the indenture;
and
|
●
|
certain
other conditions are met.
|
●
|
default
in the payment of any interest upon any debt security of that series when
it becomes due and payable, and continuance of that default for a period
of 30 days (unless the entire amount of such payment is deposited by
us with the trustee or with a paying agent prior to the expiration of the
30-day period);
|
●
|
default
in the payment of principal of or premium on any debt security of that
series when due and payable; default in the deposit of any sinking fund
payment, when and as due in respect of any debt security of that
series;
|
●
|
default
in the performance or breach of any other covenant or warranty by us in
the indenture (other than a covenant or warranty that has been included in
the indenture solely for the benefit of a series of debt securities other
than that series), which default continues uncured for a period of 60 days
after we receive written notice from the trustee or we and the trustee
receive written notice from the holders of at least 25% in principal
amount of the outstanding debt securities of that series as provided in
the indenture;
|
●
|
certain
events of bankruptcy, insolvency or reorganization; and
|
●
|
any
other event of default provided with respect to debt securities of that
series that is described in the applicable prospectus supplement
accompanying this prospectus.
|
●
|
that
holder has previously given to the trustee written notice of a continuing
Event of Default with respect to debt securities of that series;
and
|
●
|
the
holders of at least 25% in principal amount of the outstanding debt
securities of that series have made written request, and offered
reasonable indemnity, to the trustee to institute such proceeding as
trustee, and the trustee shall not have received from the holders of a
majority in principal amount of the outstanding debt securities of that
series a direction inconsistent with that request and has failed to
institute the proceeding within 90
days.
|
●
|
change
the amount of debt securities whose holders must consent to an amendment
or waiver;
|
●
|
reduce
the rate of or extend the time for payment of interest (including default
interest) on any debt security;
|
●
|
reduce
the principal of or premium on or change the fixed maturity of any debt
security or reduce the amount of, or postpone the date fixed for, the
payment of any sinking fund or analogous obligation with respect to any
series of debt securities;
|
●
|
reduce
the principal amount of discount securities payable upon acceleration of
maturity;
|
●
|
waive
a default in the payment of the principal of, premium or interest on any
debt security (except a rescission of acceleration of the debt securities
of any series by the holders of at least a majority in aggregate principal
amount of the then outstanding debt securities of that series and a waiver
of the payment default that resulted from that
acceleration);
|
●
|
make
the principal of or premium or interest on any debt security payable in
currency other than that stated in the debt security;
|
●
|
make
any change to certain provisions of the indenture relating to, among other
things, the right of holders of debt securities to receive payment of the
principal of, premium and interest on those debt securities and to
institute suit for the enforcement of any payment and to waivers or
amendments; or
|
●
|
waive
a redemption payment with respect to any debt security or change any of
the provisions with respect to the redemption of any debt
securities.
|
●
|
we
may omit to comply with the restrictive covenants contained in the
indenture, as well as any additional covenants contained in a supplement
to the indenture, a board resolution or an officers’ certificate delivered
pursuant to the indenture; and
|
●
|
Events
of Default under the indenture will not constitute a default or an Event
of Default with respect to the debt securities of that
series.
|
The
conditions include:
|
|
●
|
depositing
with the trustee money and/or U.S. Government Obligations, that, through
the payment of interest and principal in accordance with their terms, will
provide money in an amount sufficient in the opinion of a nationally
recognized firm of independent public accountants to pay principal,
premium and interest on and any mandatory sinking fund payments in respect
of the debt securities of that series on the stated maturity of those
payments in accordance with the terms of the indenture and those debt
securities; and
|
●
|
delivering
to the trustee an opinion of counsel to the effect that the holders of the
debt securities of that series will not recognize income, gain or loss for
U.S. federal income tax purposes as a result of the deposit and related
covenant defeasance and will be subject to U.S. federal income tax in the
same amount and in the same manner and at the same times as would have
been the case if the deposit and related covenant defeasance had not
occurred.
|
●
|
the
title of the convertible debt securities;
|
●
|
the
price or prices (expressed as a percentage of the aggregate principal
amount) at which we will sell the convertible debt
securities;
|
●
|
any
limit on the aggregate principal amount of the convertible debt
securities;
|
●
|
the
date or dates on which we will pay the principal on the convertible debt
securities;
|
●
|
the
rate or rates (which may be fixed or variable) per annum or the method
used to determine the rate or rates (including any commodity, commodity
index, stock exchange index or financial index) at which the convertible
debt securities will bear interest, the date or dates from which interest
will accrue, the date or dates on which interest will commence and be
payable and any regular record date for the interest payable on any
interest payment date;
|
●
|
the
place or places where principal of, premium, and interest on the
convertible debt securities will be payable;
|
●
|
the
terms and conditions upon which we may redeem the convertible debt
securities;
|
●
|
the
terms and conditions upon which the convertible debt securities will be
convertible into our ordinary shares (including ordinary shares
represented by ADSs) or exchangeable for other of our securities, and if
so, the terms of conversion or exchange;
|
●
|
any
obligation we have to redeem or purchase the convertible debt securities
pursuant to any sinking fund or analogous provisions or at the option of a
holder of convertible debt
securities;
|
●
|
the
dates on which and the price or prices at which we will repurchase the
convertible debt securities at the option of the holders of debt
securities and other detailed terms and provisions of these repurchase
obligations;
|
●
|
the
denominations in which the convertible debt securities will be issued, if
other than in denominations of $1,000 and any integral multiple
thereof;
|
●
|
whether
the convertible debt securities will be issued in the form of certificated
convertible debt securities or global convertible debt
securities;
|
●
|
the
portion of principal amount of the convertible debt securities payable
upon declaration of acceleration of the maturity date, if other than the
principal amount;
|
●
|
the
manner in which the amounts of payment of principal of, premium or
interest on the convertible debt securities will be determined, if these
amounts may be determined by reference to an index based on a currency or
currencies other than that in which the convertible debt securities are
denominated or designated to be payable or by reference to a commodity,
commodity index, stock exchange index or financial
index;
|
●
|
any
provisions relating to any security provided for the convertible debt
securities;
|
●
|
any
addition to or change in the Events of Default described in this
prospectus or in the indenture with respect to the convertible debt
securities and any change in the acceleration provisions described in this
prospectus or in the indenture with respect to the convertible debt
securities;
|
●
|
any
addition to or change in the covenants described in this prospectus or in
the indenture with respect to the convertible debt
securities;
|
●
|
any
other terms of the convertible debt securities, which may modify or delete
any provision of the indenture as it applies to that series;
and
|
●
|
any
depositaries, interest rate calculation agents, exchange rate calculation
agents or other agents with respect to the convertible debt
securities.
|
●
|
the
successor person is a corporation, limited liability company, partnership,
trust or other entity organized and validly existing under the laws of the
Republic of Ireland or any U.S. domestic jurisdiction and expressly
assumes our obligations on the convertible debt securities and under the
indenture;
|
●
|
immediately
after giving effect to the transaction, no Event of Default, and no event
which, after notice or lapse of time, or both, would become an Event of
Default, shall have occurred and be continuing under the indenture;
and
|
●
|
certain
other conditions are met.
|
●
|
default
in the payment of any interest upon any convertible debt security of that
series when it becomes due and payable, and continuance of that default
for a period of 30 days (unless the entire amount of such payment is
deposited by us with the trustee or with a paying agent prior to the
expiration of the 30-day period);
|
●
|
default
in the payment of principal of or premium on any convertible debt security
of that series when due and payable; default in the deposit of any sinking
fund payment, when and as due in respect of any convertible debt security
of that series;
|
●
|
default
in the performance or breach of any other covenant or warranty by us in
the indenture (other than a covenant or warranty that has been included in
the indenture solely for the benefit of a series of convertible debt
securities other than that series), which default continues uncured for a
period of 60 days after we receive written notice from the trustee or
we and the trustee receive written notice from the holders of at least 25%
in principal amount of the outstanding convertible debt securities of that
series as provided in the indenture;
|
●
|
certain
events of bankruptcy, insolvency or reorganization; and
|
●
|
any
other event of default provided with respect to convertible debt
securities of that series that is described in the applicable prospectus
supplement accompanying this
prospectus.
|
●
|
that
holder has previously given to the trustee written notice of a continuing
Event of Default with respect to convertible debt securities of that
series; and
|
●
|
the
holders of at least 25% in principal amount of the outstanding convertible
debt securities of that series have made written request, and offered
reasonable indemnity, to the trustee to institute such proceeding as
trustee, and the trustee shall not have received from the holders of a
majority in principal amount of the outstanding convertible debt
securities of that series a direction inconsistent with that request and
has failed to institute the proceeding within 90
days.
|
●
|
change
the amount of convertible debt securities whose holders must consent to an
amendment or waiver;
|
●
|
reduce
the rate of or extend the time for payment of interest (including default
interest) on any convertible debt security;
|
●
|
reduce
the principal of or premium on or change the fixed maturity of any
convertible debt security or reduce the amount of, or postpone the date
fixed for, the payment of any sinking fund or analogous obligation with
respect to any series of convertible debt securities;
|
●
|
reduce
the principal amount of discount securities payable upon acceleration of
maturity;
|
●
|
waive
a default in the payment of the principal of, premium or interest on any
convertible debt security (except a rescission of acceleration of the
convertible debt securities of any series by the holders of at least a
majority in aggregate principal amount of the then outstanding convertible
debt securities of that series and a waiver of the payment default that
resulted from that acceleration);
|
●
|
make
the principal of or premium or interest on any convertible debt security
payable in currency other than that stated in the convertible debt
security;
|
●
|
make
any change to certain provisions of the indenture relating to, among other
things, the right of holders of convertible debt securities to receive
payment of the principal of, premium and interest on those convertible
debt securities and to institute suit for the enforcement of any payment
and to waivers or amendments; or
|
●
|
waive
a redemption payment with respect to any convertible debt security or
change any of the provisions with respect to the redemption of any
convertible debt securities.
|
●
|
we
may omit to comply with the restrictive covenants contained in the
indenture, as well as any additional covenants contained in a supplement
to the indenture, a board resolution or an officers’ certificate delivered
pursuant to the indenture; and
|
●
|
Events
of Default under the indenture will not constitute a default or an Event
of Default with respect to the convertible debt securities of that
series.
|
The
conditions include:
|
|
●
|
depositing
with the trustee money and/or U.S. Government Obligations, that, through
the payment of interest and principal in accordance with their terms, will
provide money in an amount sufficient in the opinion of a nationally
recognized firm of independent public accountants to pay principal,
premium and interest on and any mandatory sinking fund payments in respect
of the convertible debt securities of that series on the stated maturity
of those payments in accordance with the terms of the indenture and those
convertible debt securities; and
|
●
|
delivering
to the trustee an opinion of counsel to the effect that the holders of the
convertible debt securities of that series will not recognize income, gain
or loss for U.S. federal income tax purposes as a result of the deposit
and related covenant defeasance and will be subject to U.S. federal income
tax in the same amount and in the same manner and at the same times as
would have been the case if the deposit and related covenant defeasance
had not occurred.
|
●
|
are
ultimately controlled by residents of a Relevant
Territory;
|
|
●
|
are
resident in a Relevant Territory and are not controlled by Irish
residents;
|
|
●
|
have
the principal class of their shares, or shares of a 75% parent,
substantially and regularly traded on one or more recognized stock
exchanges in a Relevant Territory (including Ireland) or Territories;
or
|
|
●
|
are
wholly owned by two or more companies, each of whose principal class of
shares is substantially and regularly traded on one or more recognized
stock exchanges in a Relevant Territory (including Ireland) or
Territories;
|
●
|
the
depositary has been authorized by the Irish Revenue Commissioners as a
qualifying intermediary and such authorization has not expired or been
revoked; and either
|
|
●
|
the
depositary bank’s ADS register shows that the beneficial owner has a U.S.
address on the register; or
|
|
●
|
if
there is a further intermediary between the depositary bank and the
beneficial owner, where the depositary bank receives confirmation from the
intermediary that the beneficial owner’s address in the intermediary’s
records is in the U.S.
|
●
|
an
individual resident in the U.S. or in a Relevant Territory; a corporation
that is ultimately controlled by persons resident in the U.S. or in a
Relevant Territory; a corporation whose principal class of shares (or its
75% or greater parent’s principal class of shares) is substantially and
regularly traded on a recognized stock exchange in an EU country or in a
Relevant Territory;
|
|
●
|
a
corporation resident in another EU member state or in a Relevant
Territory, which is not controlled directly or indirectly by Irish
residents; or
|
|
●
|
a
corporation that is wholly owned by two or more corporations each of whose
principal class of shares is substantially and regularly traded on a
recognized stock exchange in an EU country or in a Relevant
Territory.
|
●
|
who
cease to be Irish resident;
|
|
●
|
who
own the shares when they cease to be resident;
|
|
●
|
if
there are not more than five years of assessment between the last year of
Irish tax residence prior to becoming temporarily non-resident and the tax
year that such individual resumes Irish tax residency;
|
|
●
|
who
dispose of an interest in a company during this temporary non-residence;
and
|
|
●
|
the
interest disposed of represents 5% or greater of the share capital of the
company or is worth at least
€500,000.
|
●
|
through
underwriters;
|
|
●
|
through
dealers;
|
|
●
|
through
agents; or
|
|
●
|
directly
to purchasers.
|
●
|
the
terms of the offering, including the aggregate number of securities being
offered;
|
|
●
|
the
names of any underwriters, dealers or agents;
|
|
●
|
the
purchase price of the securities;
|
|
●
|
the
net proceeds to us from the sale of the securities;
|
|
●
|
any
delayed delivery arrangements;
|
|
●
|
any
underwriting discounts or other underwriters’ compensation;
and
|
|
●
|
any
discounts or concessions allowed or reallowed or paid to
dealers.
|
●
|
our
annual report on Form 20-F for the fiscal year ended December 31, 2008
filed with the SEC on March 31, 2009;
|
|
●
|
our
current report on Form 6-K filed with the SEC on May 19, 2009;
and
|
|
●
|
the
description of our Registration Rights Agreement, dated as of December 12,
1997, contained on Form 6-K, filed with the Commission on January 31,
2003.
|
Paragraph
139 of the Articles of Association of ICON provides as
follows:
|
||
Subject
to the provisions of and so far as may be permitted by the Acts, every
Director, Managing Director, Secretary or other officer of the Company
shall be entitled to be indemnified by the Company against all costs,
charges, losses, expenses, and liabilities incurred by him in the
execution and discharge of his duties or in relation thereto including any
liability incurred by him in defending any proceedings, civil or criminal,
which relate to anything done or omitted or alleged to have been done or
omitted by him as an officer or employee of the Company and in which
judgment is given in his favor (or the proceedings are otherwise disposed
of without any finding or admission of any material breach of duty on his
part) or in which he is acquitted or in connection with any application
under any statute for relief from liability in respect of any such act or
omission in which relief is granted to him by the Court.
|
||
To
the extent permitted by law, the Directors may arrange insurance cover at
the cost of the Company in respect of any liability, loss or expenditure
incurred by any Director or officer in relation to anything done or
alleged to have been done or omitted to be done by him as Director or
officer.
|
(a)
|
The
following exhibits are filed herewith, or incorporated by reference
herein:
|
Exhibit
Number
|
Exhibit
|
||
4.1*
|
Deposit
Agreement, dated as of May 20, 1998, between the Company, The Bank of New
York and the holders from time to time of the Company’s
ADRs.
|
||
4.2**
|
Form
of Ordinary Share certificate.
|
||
4.3*
|
Form
of ADR certificate (included in Exhibit 4.1).
|
||
4.4**
|
Registration
Rights Agreement, dated as of December 12, 1997.
|
||
5.1
|
Opinion
of A&L Goodbody Solicitors as to the validity of
securities.
|
||
5.2
|
Opinion
of Cahill Gordon & Reindel LLP as to validity of
securities.
|
||
23.1
|
Consent
of KPMG, Independent Registered Public Accounting Firm for the
Company.
|
||
23.2
|
Consent
of A&L Goodbody Solicitors (included in Exhibit
5.1).
|
||
23.3
|
Consent
of Cahill Gordon & Reindel LLP (included in Exhibit
5.2).
|
||
24.1
|
Power
of Attorney (included on signature page
hereto).
|
*
|
Incorporated
by reference from exhibits to the Company’s Registration Statement on Form
F-6 (File No. 333-13442) filed with the Commission on April 29,
1998.
|
**
|
Incorporated
by reference from exhibits to the Company’s Registration Statement on Form
F-1 (File No. 333-8672) filed with the Commission on April 23,
1998.
|
A.
|
The
undersigned registrant hereby undertakes:
|
||
1.
|
To
file, during any period in which offers or sales of the registered
securities are being made, a post-effective amendment to this Registration
Statement:
|
||
(i)
|
To
include any prospectus required by Section 10(a)(3) of the Securities Act
of 1933, as amended (the “Securities Act”);
|
||
(ii)
|
To
reflect in the prospectus any facts or events arising after the effective
date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in the Registration
Statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from
the low or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in
the effective Registration Statement;
|
||
(iii)
|
To
include any material information with respect to the plan of distribution
not previously disclosed in the Registration Statement or any material
change to such information in the Registration
Statement;
|
||
provided, however, that
paragraphs (A)(1)(i), (A)(1)(ii) and (A)(1)(iii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the
Commission by the registrant pursuant to Section 13 or Section 15(d) of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that
are incorporated by reference in the Registration Statement, or is
contained in a form of prospectus filed pursuant to Rule 424(b) that is
part of the Registration Statement.
|
|||
2.
|
That,
for the purpose of determining any liability under the Securities Act,
each post-effective amendment that contains a form of prospectus shall be
deemed to be a new registration statement relating to the securities
offered therein, and this offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof;
|
||
3.
|
To
remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the
offering.
|
||
4.
|
To
file a post-effective amendment to the Registration Statement to include
any financial statements required by Item 8.A of Form 20-F at the start of
any delayed offering or throughout a continuous offering. Financial
Statements and information otherwise required by Section 10(a)(3) of the
Securities Act need not be furnished, provided that the
registrant includes in the prospectus, by means of a post-effective
amendment, financial statements required pursuant to this paragraph (A)(4)
and other information necessary to ensure that all other information in
the prospectus is at least as current as the date of those financial
statements. Notwithstanding the foregoing, a post-effective amendment need
not be filed to include financial statements and information required by
Section 10(a)(3) of the Securities Act or Item 8.A of Form 20-F if such
financial statements and information are contained in periodic reports
filed with or furnished to the Commission by the registrant pursuant to
Section 13 or Section 15(d) of the Exchange Act that are incorporated by
reference in this Registration
Statement.
|
5.
|
That,
for the purpose of determining liability under the Securities Act to any
purchaser:
|
||
(A)
|
Each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be
deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement;
and
|
||
(B)
|
Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or
(b)(7) as part of a registration statement in reliance on Rule 430B
relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)
for the purpose of providing the information required by section 10(a) of
the Securities Act shall be deemed to be part of and included in the
registration statement as of the earlier of the date such form of
prospectus is first used after effectiveness or the date of the first
contract of sale of securities in the offering described in the
prospectus. As provided in Rule 430B, for liability purposes of the issuer
and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement relating
to the securities in the registration statement to which that prospectus
relates, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof, provided, however, that no
statement made in a registration statement or prospectus that is part of
this Registration Statement or made in a document incorporated or deemed
incorporated by reference into this Registration Statement or prospectus
that is part of this Registration Statement will, as to a purchaser with a
time of contract of sale prior to such effective date, supersede or modify
any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document
immediately prior to such effective date.
|
||
6.
|
That,
for purposes of determining any liability under the Securities Act, each
filing of the registrant’s annual report pursuant to Section 13(a) or
Section 15(d) of the Exchange Act (and, where applicable, each filing of
an employee benefit plan’s annual report pursuant to Section 15(d) of the
Exchange Act), that is incorporated by reference in this Registration
Statement shall be deemed to be a new registration statement relating to
the securities offered therein, and this offering of such securities at
that time shall be deemed to be the initial bona fide offering
thereof;
|
||
7.
|
To
deliver or cause to be delivered with the prospectus, to each person to
whom the prospectus is sent or given, the latest annual report to security
holders that is incorporated by reference in the prospectus and furnished
pursuant to and meeting the requirements of Rule 14a-3 or Rule 14c-3 under
the Exchange Act; and, where interim financial information required to be
presented by Article 3 of Regulation S-X is not set forth in the
prospectus, to deliver, or cause to be delivered to each person to whom
the prospectus is sent or given, the latest quarterly report that is
specifically incorporated by reference in the prospectus to provide such
interim financial information; and
|
8.
|
That,
for the purpose of determining liability of the registrant under the
Securities Act to any purchaser in the initial distribution of the
securities, the undersigned registrant undertakes that in a primary
offering of securities of the undersigned registrant pursuant to this
registration statement, regardless of the underwriting method used to sell
the securities to the purchaser, if the securities are offered or sold to
such purchaser by means of any of the following communications, the
undersigned registrant will be a seller to the purchaser and will be
considered to offer or sell such securities to such
purchaser:
|
||
(i)
|
Any
preliminary prospectus or prospectus of the undersigned registrant
relating to the offering required to be filed pursuant to Rule
424;
|
||
(ii)
|
Any
free writing prospectus relating to the offering prepared by or on behalf
of the undersigned registrant or used or referred to by the undersigned
registrant;
|
||
(iii)
|
The
portion of any other free writing prospectus relating to the offering
containing material information about the undersigned registrant or its
securities provided by or on behalf of the undersigned registrant;
and
|
||
(iv)
|
Any
other communication that is an offer in the offering made by the
undersigned registrant to the
purchaser.
|
ICON
plc
|
|||
By:
|
/s/
Ciaran Murray
|
||
Ciaran
Murray
|
|||
Chief
Financial Officer
|
Name
|
Capacity
|
|||
/s/ Dr. John Climax
|
Chairman
of the Board, Director
|
|||
Dr.
John Climax
|
||||
/s/ Peter Gray
|
Chief
Executive Officer, Director
|
|||
Peter
Gray
|
||||
/s/ Ciaran Murray
|
Chief
Financial Officer
|
|||
Ciaran
Murray
|
(Principal
Financial and Accounting Officer)
|
|||
/s/ Dr. Ronan Lambe
|
Director
|
|||
Dr.
Ronan Lambe
|
||||
/s/ Thomas Lynch
|
Director
|
|||
Thomas
Lynch
|
||||
/s/ Edward Roberts
|
Director
|
|||
Edward
Roberts
|
||||
/s/ Dr. Bruce Given
|
Director
|
|||
Dr.
Bruce Given
|
||||
/s/ Dermot Kelleher
|
Director
|
|||
Prof.
Dermot Kelleher
|
||||
/s/ Dr. Anthony J. Murphy
|
Director
|
|||
Dr.
Anthony J. Murphy
|
||||
/s/ Donald J. Puglisi
|
Authorized
Representative in the U.S.
|
|||
Donald
J. Puglisi
|
||||
Title:
Managing Director
|
||||
Puglisi
& Associates
|
|
|||
Exhibit
Number
|
Exhibit
|
||
4.1*
|
Deposit
Agreement, dated as of May 20, 1998, between the Company, The Bank of New
York and the holders from time to time of the Company’s
ADRs.
|
||
4.2**
|
Form
of Ordinary Share certificate.
|
||
4.3*
|
Form
of ADR certificate.
|
||
4.4**
|
Registration
Rights Agreement, dated as of December 12, 1997.
|
||
5.1
|
Opinion
of A&L Goodbody Solicitors as to validity of
securities.
|
||
5.2
|
Opinion
of Cahill Gordon & Reindel LLP as to validity of
securities.
|
||
23.1
|
Consent
of KPMG, Independent Registered Public Accounting Firm for the
Company.
|
||
23.2
|
Consent
of A&L Goodbody Solicitors (included in Exhibit
5.1).
|
||
23.3
|
Consent
of Cahill Gordon & Reindel LLP (included in Exhibit
5.2).
|
||
24.1
|
Power
of Attorney (included on signature page
hereto).
|
*
|
Incorporated
by reference from exhibits to the Company’s Registration Statement on Form
F-6 (File No. 333-13442) filed with the Commission on April 29,
1998.
|
**
|
Incorporated
by reference from exhibits to the Company’s Registration Statement on Form
F-1 (File No. 333-8672) filed with the Commission on April 23,
1998.
|